Irodalom:
1. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after
Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006 Jan 1;23 (1):35-44.
2. Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, Chan AO, Lai KC, Chan CK, WongBC.
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment
of resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006 1;23 (3):421-7.
3. Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. A study of
4 — and 7 — day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment
Gyógyszerek 475
for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2006 Jan 15;23 (2):281-7.
4. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based
quadruple therapy for persistent Helicobacter pylori infection: a meta- analysis. Am J Gastroenterol.
2006 Mar;101 (3):488-96.
5. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM.: Third-line rescue therapy with levofloxacin
is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment
Pharmacol Ther. 2006 Oct 10.
6. Gisbert JP, Castro-Fernandez M, Bermejo F, Perez-Aisa A, Ducons J, Fernandez-Bermejo M, Bory F,
Cosme A, Benito LM, Lopez-Rivas L, Lamas E, Pabon M, Olivares D; The H. pylori Study Group of
the Asociacion Espanola de Gastroenterologia. Third-line rescue therapy with levofloxacin after two H.
pylori treatment failures. Am J Gastroenterol. 2006 Feb;101 (2):243-7.
7. Antos D, Schneider-Brachert W, Bastlein E, Hanel C, Haferland C, Buchner M, Meier E, Trump F,
Stolte M, Lehn N, Bayerdorffer E. 7-day triple therapy of Helicobacter pylori infection with levofloxacin,
amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter.
2006 Feb;11 (1):39-45.
8. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini
G, Gasbarrini A. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Am J Gastroenterol. 2006 Sep;101 (9):1985-90.
9. Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. Can
Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized,
pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin
Gastroenterol. 2006 Jul;40 (6):515-20.
10. Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Fujioka T, Kodama M, Abe T, Sato S, Arita T.
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J
Gastroenterol Hepatol. 2006 Jan;21 (1 Pt 2):262-7.
11. Graham DY, Abudayyeh S, El-Zimaity HM, Hoffman J, Reddy R, Opekun AR. Sequential therapy using
high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection.
Aliment Pharmacol Ther. 2006 Sep 1;24 (5):845-50.
12. Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Bastlein E,
Jacobs E, Bayerdorffer E, Lehn N, Stolte M. Randomized trial of rifabutin-based triple therapy and
high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and
clarithromycin. Aliment Pharmacol Ther. 2006 Jul 15;24 (2):395-403
13. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, Llorente R, Ng C. Efficacy and
safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment
Pharmacol Ther. 2006 Feb 15;23 (4):481-8.
14. Taylor DN, McKenzie R, Durbin A, Carpenter C, Atzinger CB, Haake R, Bourgeois AL. Rifaximin, a
nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006
May 1;42 (9):1283-8.
15. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral ntibiotic (rifaximin)
on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006 Oct
17;145 (8):557-63.
16. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-lind placebocontrolled
trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol.
2006 Feb;101 (2):326-33.
17. Taylor DN, McKenzie R, Durbin A, Carpenter C, Atzinger CB, Haake R, Bourgeois AL. Rifaximin, a
nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006
May 1;42 (9):1283-8.
18. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Antibiotic
treatment of Crohn’s disease: results of a multicentre, double blind,randomized, placebo-controlled trial
476 Gastro Update 2007
with rifaximin. Aliment Pharmacol Ther. 2006 Apr 15;23 (8):1117-25.
19. Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang ZD, Halpern J, Haake R, Dupont HL. A ran
domized, double-blind, multicenter study of rifaximin compared with placebo and withciprofloxacin in
the treatment of travelers’ diarrhea. Am J Trop Med Hyg. 2006 Jun;74 (6):1060-6.
20. Zamir D, Weiler Z, Kogan E, Ben-Valid E, Hay E, Reitblat T, Polishchuk I. Single-dose quinolone treatment
of acute gastroenteritis. J Clin Gastroenterol. 2006 Mar;40 (3):186-90.
21. Milazzo L, Biasin M, Gatti N, Piacentini L, Niero F, Zanone Poma B, Galli M, Moroni M, Clerici M,
Riva A. Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and rib
avirin. Am J Gastroenterol. 2006 Feb;101 (2):399-402.
22. Balan V, Rosati MJ, Anderson MH, Rakela J. Successful treatment with novel triple drug com bination
consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to
pegylated interferon therapy. Dig Dis Sci. 2006 May;51 (5):956-9.
23. Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, Marschal O, Steffen M,
Manns MP, Wedemeyer H. Treatment with daily consensus interferon (CIFN) plus ribavirin in nonresponder
patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol. 2006
Feb;44 (2):291-301.
24. Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs.
2006;66 (12):1605-22;
25. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P,
Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R; AI463026 BEHoLD Study Group.
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Gastroenterology. 2006 Jun;130 (7):2039-49.
26. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J,
Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison
of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006 Mar
9;354 (10):1001-10.
27. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC,
Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for
patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006 Mar 9; 354 (10):1011-20.
28. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco
C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside
naive patients with hepatitis B. Hepatology. 2006 Dec;44 (6):1656-65.
29. Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, Barker KF. A double-blind randomized
trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology.
2006 Jul;44 (1):108-16.
30. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased
risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of
adefovir dipivoxil monotherapy. Hepatology. 2006 Jun;43 (6):1385-91.
31. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, Byun KS,
Lee CH. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated
with adefovir dipivoxil Gut. 2006 Oct;55 (10):1488-95.
32. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA,
Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B; ACTG Protocol A5127 Team.
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection:
ACTG A5127. Hepatology. 2006 Nov;44 (5):1110-6.
33. van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, Feucht HH, Wiedenmann B,
Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high
HBV DNA level during adefovir therapy. Hepatology. 2006 Aug;44 (2):318-25.
34. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, Lee SS, Chan S, Shiffman ML, Washington
Gyógyszerek 477
MK, Rigney A, Anderson J, Mondou E, Snow A, Sorbel J, Guan R, Rousseau F; Emtricitabine FTCB301
Study Group. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch
Intern Med. 2006 Jan 9;166 (1):49-56.
35. Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, Mondou E, Snow A, Sorbel J, Rousseau F.
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment
of chronic hepatitis B. Antimicrob Agents Chemother. 2006 May; 50 (5):1642-8.
36. Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, Yoo K, Yoo HW, Lee JH, Yoo BC.A 12-week
clevudine therapy showed potent and durable antiviral activity in hbeag-positive chronic hepatitis B.
Hepatology. 2006 May;43 (5):982-8.
37. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing
recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized,
open-label study. J Clin Gastroenterol. 2006 Apr;40 (4):312-6.
38. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, Fernandez-Carbia A, Salgado-Mercado
R, Marxuach-Cuetara AM. Double-blind pilot study of mesalamine vs. placebo for treatment of chronic
diarrhea and nonspecific colitis in immunocompetent HIV patients. Dig Dis Sci. 2006 Jan;51 (1):161-7.
39. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D,
Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease:
the CLASSIC-I trial. Gastroenterology. 2006 Feb;130 (2):323-33;
40. Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. CDP571, a humanized
monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn’s disease: a randomized,
double-blind,placebo-controlled trial. Aliment Pharmacol Ther. 2006 Mar 1;23 (5):617-28.
41. Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK. Bioavailability and therapeutic
activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active
ulcerative colitis. Aliment Pharmacol Ther. 2006 May 15;23 (10):1427-34.
42. Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsenenema
compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized,
double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006 May 15;23 (10):1403-13.
43. van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. A phase II dose ranging, doubleblind,
placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to
moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006 May 15; 23 (10):1415-25.
44. Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson
FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames
RS. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment
of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose
ranging trial. Gut. 2006 Nov;55 (11):1568-74
45. Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM; BASBUC
INVESTIGATORS. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience
in moderate and severe disease. Aliment Pharmacol Ther. 2006 May 15; 23 (10):1435-42.
46. Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, Boerner N,
Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M, Stange EF. Randomized, double
blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active
Crohn’s disease. Am J Gastroenterol. 2006 Apr;101 (4):793-7.
47. Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuciova M, D’Haens G,
Van Assche G, Ba S, Lee S, Pearce T. Fontolizumab, a humanised anti-interferon gamma antibody,
demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut. 2006
Aug;55 (8):1131-7.
48. Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K,
Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. A dose escalating, placebo
controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a
478 Gastro Update 2007
humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn’s disease. Gut.
2006 Aug;55 (8):1138-44
49. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in
patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease — a long-term
follow-up. Am J Gastroenterol. 2006 May;101 (5):1048-56.
50. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding
study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006 Sep;55 (9):1255-62.
51. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis.
Gastroenterology. 2006 May;130 (6):1707-20.
52. McKeage K, Plosker GL, Siddiqui MA. Lubiprostone. Drugs. 2006;66 (6):873-9
53. Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K, McKinzie S, Zinsmeister AR.
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory,
and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006 May;290
(5):G942-7.
54. Moeser A, Nighot PK, Engelke K, Ueno R, Blikslager AT. Recovery of Mucosal Barrier Function in
Ischemic Porcine Ileum and Colon is Stimulated by a Novel Agonist of the ClC-2 Chloride Channel,
Lubiprostone. Am J Physiol Gastrointest Liver Physiol. 2006 Oct 19
55. Tack J, Middleton SJ, Horne MC, Piessevaux H, Bloor JS, Meyers NL, Palmer RM. Pilot study of the
efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant
irritable bowel syndrome. Aliment Pharmacol Ther. 2006 Jun 1;23 (11):1655-65.
56. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB,
Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J,
Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B,
Sylwestrowicz T, Gordon GB, Hawk ET: APC Study Investigators. Celecoxib for the prevention of
sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31;355(9):873-84.
57. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J,
Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP
Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006
Aug 31;355 (9):885-95.
58. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity
of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006
Feb;101 (2):311-7.
59. Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W, Schroder H, Pohle T. Beyond gastric
acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells.
Biochem Biophys Res Commun. 2006 Jul 7;345 (3):1014-21.
60. Shimatani T, Inoue M, Kuroiwa T, Xu J, Nakamura M, Tazuma S, Ikawa K, orikawa N. Lafutidine, a
newly developed antiulcer drug, elevates postprandial intragastricpH and increases plasma calcitonin
gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis
Sci. 2006 Jan;51 (1):114-20.
61. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot
study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol
Ther. 2006 Jun 1;23 (11):1643-7.
62. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and
their potential for combination therapy with interferon. Hepatology. 2006 Jul;44 (1):117-25.
63. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C.
Clin Gastroenterol Hepatol. 2006 Jul;4 (7):902-7.
64. Deibert P, Schumacher YO, Ruecker G, Opitz OG, Blum HE, Rossle M, Kreisel W. Effect of vardenafil,
an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver — results of
Gyógyszerek 479
a pilot study. Aliment Pharmacol Ther. 2006 Jan 1;23 (1):121-8.
65. Thuluvath PJ, Maheshwari A, Wong F, Yoo HW, Schrier RW, Parikh C, Steare S, Korula J. Oral V2
receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind,
placebo-controlled, single ascending dose study. Aliment Pharmacol Ther. 2006 Sep 15;24 (6):973-82.
66. Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension
related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest. 2006 Sep;36 Suppl 3:67-70.
67. Barth F, Gerber PJ, Reichen J, Dufour JF, Nicod LP. Efficiency and safety of bosentan in child C cirrhosis
with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol. 2006
Oct;18 (10):1117-9.
68. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment
Pharmacol Ther. 2006 Sep 15;24 (6):935-44.
69. Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced
circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol. 2006 Jan;21 (1 Pt 2):
303-7.
70. Lee HR. Pimentel M: Bacteria and irritable bowel syndrome: the evidenve for small intestinal bacterial
overgrowth Current Gastroenterology Reports 2006;8:305-11
